• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CLCN7 依赖性成骨不全症的分子和临床异质性:20 种新突变的报告。

Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations.

机构信息

Institute of Biomedical Technologies, National Research Council, 20090 Segrate, Italy.

出版信息

Hum Mutat. 2010 Jan;31(1):E1071-80. doi: 10.1002/humu.21167.

DOI:10.1002/humu.21167
PMID:19953639
Abstract

The "Osteopetroses" are genetic diseases whose clinical picture is caused by a defect in bone resorption by osteoclasts. Three main forms can be distinguished on the basis of severity, age of onset and means of inheritance: the dominant benign, the intermediate and the recessive severe form. While several genes have been involved in the pathogenesis of the different types of osteopetroses, the CLCN7 gene has drawn the attention of many researchers, as mutations within this gene are associated with very different phenotypes. We report here the characterization of 25 unpublished patients which has resulted in the identification of 20 novel mutations, including 11 missense mutations, 6 causing premature termination, 1 small deletion and 2 putative splice site defects. Careful analysis of clinical and molecular data led us to several conclusions. First, intermediate osteopetrosis is not homogeneous, since it can comprise both severe dominant forms with an early onset and recessive ones without central nervous system involvement. Second, the appropriateness of haematopoietic stem cell transplantation in CLCN7-dependent ARO patients has to be carefully evaluated and exhaustive CNS examination is strongly suggested, as transplantation can almost completely cure the disease in situations where no primary neurological symptoms are present. Finally, the analysis of this largest cohort of CLCN7-dependent ARO patients together with some ADO II families allowed us to draw preliminary genotype-phenotype correlations suggesting that haploinsufficiency is not the mechanism causing ADO II. The availability of biochemical assays to characterize ClC-7 function will help to confirm this hypothesis.

摘要

“骨质硬化症”是一种遗传性疾病,其临床表现是由于破骨细胞的骨吸收缺陷引起的。根据严重程度、发病年龄和遗传方式,可将其分为三种主要形式:显性良性、中间型和隐性严重型。虽然有几个基因已涉及不同类型的骨质硬化症的发病机制,但 CLCN7 基因引起了许多研究人员的关注,因为该基因内的突变与非常不同的表型相关。我们在此报告了 25 例未发表的患者的特征,这些患者的特征导致了 20 种新突变的鉴定,包括 11 种错义突变、6 种导致提前终止、1 种小缺失和 2 种可能的剪接位点缺陷。对临床和分子数据的仔细分析使我们得出了几个结论。首先,中间型骨质硬化症并不均质,因为它既可以包括早发的严重显性形式,也可以包括无中枢神经系统受累的隐性形式。其次,CLCN7 依赖性 ARO 患者造血干细胞移植的适宜性必须仔细评估,并强烈建议进行全面的中枢神经系统检查,因为在没有原发性神经系统症状的情况下,移植几乎可以完全治愈疾病。最后,对这一大群 CLCN7 依赖性 ARO 患者的分析以及一些 ADO II 家族的分析使我们能够得出初步的基因型-表型相关性,表明单倍不足不是导致 ADO II 的机制。用于表征 ClC-7 功能的生化测定法的可用性将有助于证实这一假设。

相似文献

1
Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations.CLCN7 依赖性成骨不全症的分子和临床异质性:20 种新突变的报告。
Hum Mutat. 2010 Jan;31(1):E1071-80. doi: 10.1002/humu.21167.
2
Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis.氯离子通道ClCN7突变是导致严重隐性、显性和中间型骨硬化症的原因。
J Bone Miner Res. 2003 Oct;18(10):1740-7. doi: 10.1359/jbmr.2003.18.10.1740.
3
Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.CLCN7基因的新型突变在中国患者中导致常染色体显性II型骨硬化症(ADO-II)和中间型常染色体隐性骨硬化症(IARO)。
Osteoporos Int. 2016 Mar;27(3):1047-1055. doi: 10.1007/s00198-015-3320-x. Epub 2015 Sep 22.
4
Identification of two novel mutations on CLCN7 gene in a patient with malignant ostopetrosis.一名恶性骨硬化症患者CLCN7基因两个新突变的鉴定。
Ital J Pediatr. 2014 Nov 20;40:90. doi: 10.1186/s13052-014-0090-6.
5
Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADOII) and intermediate autosomal recessive osteopetrosis (ARO) in seven Chinese families.CLCN7基因的新型突变在七个中国家庭中导致了常染色体显性II型骨硬化症(ADOII)和中间型常染色体隐性骨硬化症(ARO)。
Postgrad Med. 2017 Nov;129(8):934-942. doi: 10.1080/00325481.2017.1386529. Epub 2017 Oct 11.
6
Identification of TCIRG1 and CLCN7 gene mutations in a patient with autosomal recessive osteopetrosis.一名常染色体隐性遗传性骨硬化症患者中TCIRG1和CLCN7基因突变的鉴定。
Mol Med Rep. 2014 Apr;9(4):1191-6. doi: 10.3892/mmr.2014.1955. Epub 2014 Feb 17.
7
Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation.常染色体显性遗传性骨硬化症:94例氯离子通道7基因突变患者的临床严重程度及自然病史。
J Clin Endocrinol Metab. 2007 Mar;92(3):771-8. doi: 10.1210/jc.2006-1986. Epub 2006 Dec 12.
8
Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene.阿尔伯斯-尚伯格病(常染色体显性遗传性骨硬化症II型)由ClCN7氯通道基因突变引起。
Hum Mol Genet. 2001 Dec 1;10(25):2861-7. doi: 10.1093/hmg/10.25.2861.
9
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.49例骨质石化症患者的临床、遗传及细胞分析:对诊断和治疗的意义
J Med Genet. 2006 Apr;43(4):315-25. doi: 10.1136/jmg.2005.036673. Epub 2005 Aug 23.
10
The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families.中国人骨肉瘤的毒力基因和临床表型:12 个骨肉瘤家庭的 CLCN7 基因的 6 个新突变。
J Bone Miner Metab. 2012 May;30(3):338-48. doi: 10.1007/s00774-011-0319-z. Epub 2011 Sep 28.

引用本文的文献

1
Genetic testing confirmed osteopetrosis with initial presentation of nystagmus.基因检测确诊为骨质石化症,最初表现为眼球震颤。
Taiwan J Ophthalmol. 2023 Apr 28;14(3):437-440. doi: 10.4103/tjo.TJO-D-22-00152. eCollection 2024 Jul-Sep.
2
Molecular Heterogeneity of Osteopetrosis in India: Report of 17 Novel Variants.印度骨硬化症的分子异质性:17个新变体的报告。
Indian J Hematol Blood Transfus. 2024 Jul;40(3):494-503. doi: 10.1007/s12288-023-01732-4. Epub 2024 Jan 12.
3
Autosomal Dominant Osteopetrosis (ADO) Caused by a Missense Variant in the TCIRG1 Gene.
常染色体显性骨硬化症(ADO)由 TCIRG1 基因中的错义变异引起。
J Clin Endocrinol Metab. 2024 Jun 17;109(7):1726-1732. doi: 10.1210/clinem/dgae040.
4
Vesicular CLC chloride/proton exchangers in health and diseases.健康与疾病中的囊泡型CLC氯离子/质子交换体
Front Pharmacol. 2023 Nov 7;14:1295068. doi: 10.3389/fphar.2023.1295068. eCollection 2023.
5
Biophysical Aspects of Neurodegenerative and Neurodevelopmental Disorders Involving Endo-/Lysosomal CLC Cl/H Antiporters.涉及内体/溶酶体CLC氯/氢反向转运体的神经退行性和神经发育障碍的生物物理方面
Life (Basel). 2023 Jun 2;13(6):1317. doi: 10.3390/life13061317.
6
A novel compound heterozygous mutation of the gene is associated with autosomal recessive osteopetrosis.该基因的一种新型复合杂合突变与常染色体隐性骨硬化症相关。
Front Pediatr. 2023 Apr 24;11:978879. doi: 10.3389/fped.2023.978879. eCollection 2023.
7
Clinical and genetic diagnosis of autosomal dominant osteopetrosis type II in a Chinese family: A case report.一个中国家庭中II型常染色体显性骨硬化症的临床与基因诊断:病例报告
World J Clin Cases. 2023 Jan 26;11(3):700-708. doi: 10.12998/wjcc.v11.i3.700.
8
Anterior cruciate ligament rupture in a patient with Albers-Schonberg disease.阿尔伯斯-施恩伯格病患者的前交叉韧带断裂。
BMC Musculoskelet Disord. 2022 Jul 28;23(1):719. doi: 10.1186/s12891-022-05687-x.
9
A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene.一种表现为常染色体隐性遗传骨硬化症的轻度病例,其表现形式为 CLCN7 基因中的纯合深内含子变异导致的显性形式。
Calcif Tissue Int. 2022 Oct;111(4):430-444. doi: 10.1007/s00223-022-00988-8. Epub 2022 May 26.
10
The Role of the Lysosomal Cl/H Antiporter ClC-7 in Osteopetrosis and Neurodegeneration.溶酶体 Cl-/H+ 反向转运蛋白 ClC-7 在骨质硬化症和神经退行性变中的作用。
Cells. 2022 Jan 21;11(3):366. doi: 10.3390/cells11030366.